Biographical Sketch
Thomas Robert Gildea, MD, FCCP, was appointed to Cleveland Clinic in 2003 in the Advanced Lung Disease Section of the Department of Pulmonary Allergy and Critical Care Medicine.
He is board-certified in internal medicine, pulmonary disease and critical care medicine. As a Chief Resident in the Yale Primary Care Internal Medicine residency, he went to Russia in a faculty exchange program to lecture and demonstrate American medical team structure and the basics of clinical epidemiology.
He has advanced training in interventional and advanced diagnostic bronchoscopy, which was part of his fellowship training at Cleveland Clinic. His clinical interests span the realm of advanced lung diseases, including lung volume reduction, lung transplantation, pulmonary arterial hypertension and are most focused on advanced diagnostic and therapeutic bronchoscopy.
Dr. Gildea was the first physician in North America to perform electromagnetic navigation bronchoscopy. He was given an Innovator Award at Cleveland Clinic in 2005 with his team proposing a novel device for a bronchoscopy needle-delivered fiducial lung implant. He has been named one of the Best Doctors in America. He also received a physician development award by the AlphaOne Foundation to study lung function changes after lung transplantation. Under his co-direction, the Center for Major Airway Diseases has brought together teams from Thoracic surgery and ENT for complex airway disease management.
An invited lecturer at national and international medical meetings, Dr. Gildea is recognized expert in the field on interventional pulmonary medicine.
Specialty Interests
advanced diagnostic and therapeutic bronchoscopy, Alpha-1 Antitrypsin Deficiency, interventional pulmonary medicine, lung transplantation, lung volume reduction
Innovations & Patents
First physician in North America to perform electromagnetic navigation bronchoscopy
Industry Relationships
Cleveland Clinic physicians and scientists may collaborate
with the pharmaceutical or medical device industries
to help develop medical breakthroughs or provide
medical education about recent trends. The
collaborations are reviewed as part of the Cleveland
Clinic’s procedures. The Cleveland Clinic publicly
discloses payments to its physicians and scientists
for speaking and consulting of
$5,000 or more per year, and any equity, royalties,
and fiduciary relationships in companies with which
they collaborate. In publicly disclosing this
information, the Cleveland Clinic tries to provide
information as accurately as possible about its
doctors’ connections with industry and those of their
immediate family members. As of 8/4/2008, Dr.
Gildea has reported the financial relationships
with the companies listed below. Patients should feel
free to contact their doctor about any of the
relationships and how the relationships are overseen
by the Cleveland Clinic. To learn more about the
Cleveland Clinic’s policies on collaborations with
industry and innovation management, go to
our Integrity in Innovation page.
Consulting. Dr. Gildea receives fees of $5,000 or more per year as a paid consultant or speaker for the following companies:
SuperDimension
Equity. Dr. Gildea owns stock or stock options in the following companies for activities as a founder, inventor, or consultant:
CSA Medical, Inc.
